Skip to main content

Rohit N. Kulkarni

NIH Rank #681
  • Program Leader
  • Top 5% Funded
  • R01 Holder
  • Multi-Institutional
  • Early Career
  • Diverse Portfolio

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 2237742Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

FY2026 award categories

  • Internal Medicine

NIH Funding · FY2024

Linked Award Amount
$6.8M
Full award amounts, FY2024
Award Records
9
Records listing this PI
Award-Linked Rank
#681
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Rohit N. Kulkarni. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2024 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2024 award records by amount

NIH award records listing Rohit N. Kulkarni as a PI. Multi-PI records show the full award amount for context.

  • 1RC2DK139552-01RC2
    Epitranscriptomics in human obesity and type 2 diabetes
    $2M
    award amount
  • 5U01DK137242-02U01
    Development of platforms for beta cell-specific delivery and ligand discovery
    $962.4K
    award amount
  • 5U01DK135095-03U01
    Using ex vivo, in vivo models and patient mutations to interrogate pancreatic exocrine-endocrine cross talk
    $904.1K
    award amount
  • 5R01DK133847-03R01
    Characterization of beta-cell-specific extracellular vesicle cargo as functional biomarkers for type I DM disease
    $718K
    award amount
  • 5R01DK105588-10R01
    Role of 12-lipoxygenase and 12-HETE signaling in beta-cell dysfunction
    $624.9K
    award amount
  • 5R01DK132900-02R01
    Development of platforms for sorting, production, editing of beta cells
    $623.5K
    award amount
  • 5R01DK129464-04R01
    Interrogating the ubiquitin pathway to understand and treat cytokine-induced beta-cell death in type 1 diabetes
    $512.3K
    award amount
  • 5P30DK036836-38P30
    Diabetes Research Center
    $284.3K
    award amount
  • 3R01DK105588-10S1R01
    Role of 12-lipoxygenase and 12-HETE signaling in beta-cell dysfunction
    $92.4K
    award amount

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Joslin Diabetes Center
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    $5M Cumulative Funding
  6. 2024
    Entered Top 50% Nationally
    Ranked #681
  7. 2024
    Entered Top 25% Nationally
    Ranked #681
  8. 2024
    Entered Top 10% Nationally
    Ranked #681
  9. 2024
    Entered Top 5% Nationally
    Ranked #681
  10. 2025
    $10M Cumulative Funding
  11. 2025
    Multi-Institutional Research
    Awards at 4 institutions
  12. 2025
    R01 Grant Holder
  13. 2025
    Program/Center Grant Leader